Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9

1 Jul 2020

Abstract excerpt

O-GlcNAc transferase (OGT) is a nutrient-sensitive glycosyltransferase that is overexpressed in prostate cancer, the most common cancer in males. We recently developed a specific and potent inhibitor targeting this enzyme, and here, we report a synthetic lethality screen using this compound. Our screen identified pan-cyclin-dependent kinase (CDK) inhibitor AT7519 as lethal in combination with OGT inhibition....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32611550
DOI: 10.1158/1541-7786.mcr-20-0339

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9PMID 32611550Read ↗

High OGT activity is essential for MYC-driven proliferation of prostate cancer cellsSemantic proximity Read ↗

Compromised CDK12 activity causes dependency on the non-essential spliceosome componentsSemantic proximity Read ↗

Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate CancerSemantic proximity Read ↗

Targeting CDK9: a promising therapeutic opportunity in prostate cancerSemantic proximity Read ↗

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read ↗

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Semantic proximity Read ↗

Inhibition of CDK9 activity compromises global splicing in prostate cancer cellsSemantic proximity Read ↗

A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growthSemantic proximity Read ↗

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancerSemantic proximity Read ↗

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic StrategiesSemantic proximity Read ↗

<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalitySemantic proximity Read ↗

Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous RecombinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.